Study guide
5.1 Category 1 Beyond-Use Dating & Storage Limitations
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
5.1 Category 1 Beyond-Use Dating & Storage Limitations
Key Takeaways Explain This Topic AI
Category 1 CSPs are prepared in an ISO Class 5 Primary Engineering Control (PEC), usually one located in an unclassified Segregated Compounding Area (SCA).
The beyond-use date for a Category 1 CSP is strictly capped at ≤ 12 \le 12 ≤ 12 hours at controlled room temperature ( 20 ∘ C 20^\circ\text{C} 2 0 ∘ C to 25 ∘ C 25^\circ\text{C} 2 5 ∘ C ) or ≤ 24 \le 24 ≤ 24 hours in a refrigerator ( 2 ∘ C 2^\circ\text{C} 2 ∘ C to 8 ∘ C 8^\circ\text{C} 8 ∘ C ).
Freezing Category 1 CSPs is strictly prohibited; freezing cannot be utilized to extend beyond-use dating in an SCA.
The short BUD limits reflect the absence of an ISO 7 cleanroom buffer area, which exposes the primary engineering control to variable ambient bioburden and airborne particulate fluctuations.
Last updated: September 2026
Beyond-Use Dating Fundamentals in Category 1 Environments
A Beyond-Use Date (BUD) represents the date and time after which a compounded sterile preparation must not be administered, stored, or transported. Under USP General Chapter <797> , a BUD is assigned based on two distinct considerations:
Microbiological Sterility Assurance : The likelihood that viable microorganisms have entered or multiplied within the preparation during compounding or storage.
Chemical and Physical Stability : The degradation rate of the active pharmaceutical ingredient (API), compatibility of excipients, and integrity of the container-closure system.
Important
A BUD can never exceed the shortest chemical stability limit of the drug substance or the manufacturer expiration date of any starting commercial component.
Category 1 Temperature-Specific BUD Allowances
Category 1 CSPs are defined by their preparation in an ISO Class 5 Primary Engineering Control (such as a LAFW, BSC, or CAI) situated inside an unclassified Segregated Compounding Area (SCA) or a cleanroom suite that does not meet full Category 2 criteria.
The Category 1 BUD Matrix
Storage Temperature Temperature Range Maximum Allowable Category 1 BUD
Controlled Room Temperature 20 ∘ C 20^\circ\text{C} 2 0 ∘ C to 25 ∘ C 25^\circ\text{C} 2 5 ∘ C ( 68 ∘ F 68^\circ\text{F} 6 8 ∘ F to 77 ∘ F 77^\circ\text{F} 7 7 ∘ F ) ≤ 12 \le 12 ≤ 12 hours
Refrigerated Storage 2 ∘ C 2^\circ\text{C} 2 ∘ C to 8 ∘ C 8^\circ\text{C} 8 ∘ C ( 36 ∘ F 36^\circ\text{F} 3 6 ∘ F to 46 ∘ F 46^\circ\text{F} 4 6 ∘ F ) ≤ 24 \le 24 ≤ 24 hours
Frozen Storage − 25 ∘ C -25^\circ\text{C} − 2 5 ∘ C to − 10 ∘ C -10^\circ\text{C} − 1 0 ∘ C ( − 13 ∘ F -13^\circ\text{F} − 1 3 ∘ F to 14 ∘ F 14^\circ\text{F} 1 4 ∘ F ) PROHIBITED (Cannot be frozen)
The Absolute Ban on Freezing
A major area of testing on the BCSCP exam is the prohibition of frozen storage for Category 1 CSPs. In previous iterations of USP <797>, low-risk preparations could occasionally be assigned frozen dating. Under the 2023 revision, Category 1 preparations can never be frozen . The rationale is biological: while freezing halts microbial replication, it does not destroy bacterial or fungal contaminants that may have entered the preparation during compounding in an unclassified ambient environment.
Clinical Applications and Operational Limits
Category 1 compounding is tailored for acute, rapid-turnaround clinical workflows:
Emergency Department Satellite Pharmacies : Immediate preparation of broad-spectrum antibiotic infusions (e.g., piperacillin/tazobactam, cefepime) or electrolyte boluses.
Ambulatory Surgery Centers : Daily batching of local anesthetic blocks or ophthalmic irrigations.
Outpatient Chemotherapy Infusion Centers : Patient-specific monoclonal antibody and antineoplastic infusions compounded in a C-SCA for same-day administration.
Operational Pitfall: Anticipatory Batching Traps
A hospital pharmacy compounding 50 doses of cefazolin for surgical prophylaxis cannot prepare doses 48 hours in advance using a Category 1 SCA, even if kept refrigerated. Doses exceeding 24 hours refrigerated must either be compounded under full Category 2 cleanroom conditions or discarded.
Immediate-Use Compounding Exemptions vs. Category 1 CSPs
Compounding personnel must clearly separate Category 1 CSPs from preparations made under the immediate-use provision of USP <797>. That provision covers CSPs made for direct and immediate administration that meet all seven conditions in Section 1.3 (see 1.4):
Operational Feature Immediate-Use Exemption Category 1 CSPs Category 2 CSPs
Primary Engineering Control (PEC) None required; prepared at clinical bedside, ICU, OR, or trauma bay Mandatory ISO Class 5 PEC (LAFW, BSC, CAI, or CACI) Mandatory ISO Class 5 PEC (LAFW, BSC, CAI, or CACI)
Secondary Engineering Control (SEC) Uncontrolled clinical ambient environment Segregated Compounding Area (SCA) or unclassified room ISO Class 7 Buffer Room with ISO Class 8 (or 7) Ante-Room
Maximum Component Limit Not more than 3 different sterile products ; USP <800> still governs hazardous drugs No component count limit; sterile or nonsterile components No component count limit; sterile or nonsterile components
Preparation Process Limit No set preparation time; aseptic technique and SOPs required Standard compounding batch or individual preparation Standard compounding batch or individual preparation
Administration Timing Administration must begin within 4 hours of preparation start Administration governed by assigned BUD (12h RT / 24h Fridge) Administration governed by Category 2 BUD grid (up to 45/90 days)
Storage Conditions Permitted Held only until administration begins (within 4 hours); may be batched for more than one patient if every condition is met Controlled Room Temp ( ≤ 12 h \le 12\,\text{h} ≤ 12 h ) or Refrigerated ( ≤ 24 h \le 24\,\text{h} ≤ 24 h ) Room Temp, Refrigerated, or Frozen per matrix
- Freezing Permitted Strictly prohibited Strictly prohibited Permitted (up to 45, 60, or 90 days per matrix)
- Temperature Standards, Monitoring Devices & Excursion Management (USP <659>)
Maintaining the physical and chemical stability of CSPs requires precise environmental temperature control. USP General Chapter <659> ( Packaging and Storage Requirements ) codifies standardized temperature ranges that govern compounding facilities, cleanrooms, and medical storage appliances:
Controlled Room Temperature : Maintained thermostatically between 20 ∘ C 20^\circ\text{C} 2 0 ∘ C and 25 ∘ C 25^\circ\text{C} 2 5 ∘ C ( 68 ∘ F 68^\circ\text{F} 6 8 ∘ F to 77 ∘ F 77^\circ\text{F} 7 7 ∘ F ), with temporary excursions permitted between 15 ∘ C 15^\circ\text{C} 1 5 ∘ C and 30 ∘ C 30^\circ\text{C} 3 0 ∘ C .
Refrigerated (Cold) : Maintained thermostatically between 2 ∘ C 2^\circ\text{C} 2 ∘ C and 8 ∘ C 8^\circ\text{C} 8 ∘ C ( 36 ∘ F 36^\circ\text{F} 3 6 ∘ F to 46 ∘ F 46^\circ\text{F} 4 6 ∘ F ).
Freezer : Maintained thermostatically between − 25 ∘ C -25^\circ\text{C} − 2 5 ∘ C and − 10 ∘ C -10^\circ\text{C} − 1 0 ∘ C ( − 13 ∘ F -13^\circ\text{F} − 1 3 ∘ F to 14 ∘ F 14^\circ\text{F} 1 4 ∘ F ).
Temperature Excursion Management & Mean Kinetic Temperature (MKT)
When a storage appliance experiences an excursion outside certified limits (e.g., a refrigerator temperature rises to 13 ∘ C 13^\circ\text{C} 1 3 ∘ C ), the Designated Person must execute a formal deviation investigation:
Immediate Physical Quarantine : All CSPs stored within the compromised appliance must be quarantined in an alternate calibrated appliance.
Chemical Stability Assessment : Evaluate whether active drug molecules underwent thermal degradation, denaturation, or hydrolysis.
Mean Kinetic Temperature (MKT) : MKT expresses a fluctuating temperature history as a single equivalent temperature, using the Arrhenius relationship. USP <659> uses it for manufactured products. For example, controlled cold temperature (2-8 °C) allows excursions of 0-15 °C if the calculated MKT stays at or below 8 °C. For a CSP , USP <797> 19.1 sets the rule: when a CSP is known to have been exposed outside its storage limits, a designated person must decide, from the literature or by testing, whether it keeps its integrity and quality. If that cannot be determined, the CSP is discarded. Freezing a refrigerated protein or emulsion is a separate physical failure that MKT cannot fix.